new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors




Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015023847008/27/15  new patent  Muscarinic acetylcholine receptor antagonists
22015023242308/20/15 Chemical process
32015020917807/30/15 Liquid droplet dispenser
42015020931907/30/15 Compositions comprising an antibody and camostat mesylate (cm)
52015021076707/30/15 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
62015021201607/30/15 Sample plate for an x-ray powder diffraction apparatus
72015020217207/23/15 Novel use
82015020385107/23/15 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
92015019756507/16/15 Novel ligand
102015018242707/02/15 Silica abrasive-free dentifrice composition
112015016650806/18/15 Novel compounds
122015015764006/11/15 Novel compounds
132015010817804/23/15 Re-sealable container
142015010538704/16/15 Substituted diketopiperazines and their use as oxytocin antagonists
152015009975604/09/15 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
162015009341404/02/15 Modified antigens
172015009344004/02/15 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
182015008034303/19/15 Benzofuran compounds for the treatment of hepatitis c virus infections
192015008036903/19/15 Novel compounds
202015006420103/05/15 Antigen binding proteins to oncostatin m (osm)
212015006550703/05/15 Novel compounds
222015004537502/12/15 Novel compounds
232015000410501/01/15 Novel composition
242014037848712/25/14 Tricyclic compounds, preparation methods, and their uses
252014037126412/18/14 Muscarinic acetylcholine receptor antagonists
262014033508311/13/14 Methods of treatment and prevention of eye diseases
272014031197710/23/14 Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
282014028813309/25/14 3 -amino- pyrazole derivatives useful against tuberculosis
292014022725908/14/14 Modified proteins and peptides
302014022726408/14/14 Drug fusions and conjugates with extended half life
312014020560407/24/14 Antigen binding constructs
322014020566107/24/14 Formulation for retinoid-containing soft gelatin capsules
332014020021807/17/14 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
342014019340707/10/14 Drug fusions and conjugates
352014018775007/03/14 Methods for selecting protease resistant polypeptides
362014017971506/26/14 2,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
372014015870406/12/14 Medicament dispenser
382014014099605/22/14 Anti-serum albumin biding variable domains
392014011643405/01/14 Dry powder inhaler compositions
402014011292904/24/14 Tumour necrosis factor receptor 1 antagonists
412014011388804/24/14 Novel combination of therapeutic agents
422014011392204/24/14 Compounds
432014010589404/17/14 Humanized anti-il-18 antibodies
442014010591504/17/14 Bcma (cd269/tnfrsf17) - binding proteins
452014007631403/20/14 Manifold for use in medicament dispenser
462014008086303/20/14 Muscarinic acetylcholine receptor antagonists
472014005690002/27/14 Method for inhibiting binding to b-cell receptor
482014005810502/27/14 Substituted diketopiperazines and their use as oxytocin antagonists
492014005071902/20/14 Antibodies
502014005172002/20/14 N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
512014003898902/06/14 Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
522014002359601/23/14 Novel composition
532014002455801/23/14 Method of treatment
542014000517701/02/14 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
552014000518801/02/14 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
562013034546512/26/13 Process for the preparation of retigabine
572013033698912/19/13 Methods of identifying a patient population
582013031590111/28/13 Novel uses
592013031704111/28/13 Compounds
602013031028111/21/13 Novel antigen binding proteins
612013030233511/14/13 Ligands that bind tgf-beta receptor ii
622013026771710/10/13 Process for the preparation of atovaquone
632013026118510/03/13 Benzamide derivatives as ep4 receptor agonists
642013025172409/26/13 Antigen binding proteins to oncostatin m (osm)
652013025318809/26/13 Novel compounds
662013023750109/12/13 Benzofuran compounds for the treatment of hepatitis c virus infections
672013022420408/29/13 Method of treatment based on atad2 inhibitors
682013021315408/22/13 Method of determining cleanliness
692013021339408/22/13 Dispensing device
702013021765808/22/13 Pyrazole compounds acting against allergic, inflammatory and immune disorders
712013021089208/15/13 Method of treatment
722013020370508/08/13 Pyrazole compounds acting against allergic, immune and inflammatory conditions
732013020380208/08/13 3 -amino- pyrazole derivatives useful against tuberculosis
742013019641208/01/13 Magi polynucleotides, polypetides, and antibodies
752013018925507/25/13 Fusions and conjugates of insulinotropic agents
762013013133805/23/13 Substituted diketopiperazines as oxytocin antagonists
772013011813205/16/13 Machine and pharmaceutical and pharmaceutical-like product assembly
782013010969005/02/13 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
792013010278304/25/13 Substituted diketopiperazines and their use as oxytocin antagonists
802013007819803/28/13 Novel use
812013005337502/28/13 Amino-quinolines as kinase inhibitors
822013003947002/14/13 Sample plate for an x-ray powder diffraction apparatus
832013004098402/14/13 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
842013003001201/31/13 Compounds
852013003001501/31/13 Muscarinic acetylcholine receptor antagonists
862013002354101/24/13 Voltage-gated sodium channel blockers
872013001249101/10/13 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
882012031620212/13/12 Compounds which have activity at m1 receptor and their uses in medicine
892012030972512/06/12 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
902012030978912/06/12 Compounds which have activity at m1 receptor and their uses in medicine
912012028854411/15/12 Novel retigabine composition
922012027727911/01/12 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
932012025146810/04/12 Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
942012024074209/27/12 Novel device
952012024517109/27/12 Benzpyrazole derivatives as inhibitors of pi3 kinases
962012023855909/20/12 Novel compounds
972012023857109/20/12 Indazole derivatives as pi 3-kinase
982012023206109/13/12 Novel compounds
992012020774908/16/12 Dosing regimen
1002012020281108/09/12 Novel compounds
1012012015744606/21/12 Medical use
1022012015749106/21/12 Muscarinic acetylcholine receptor antagonists
1032012015749206/21/12 Antibiotic drug
1042012014971106/14/12 Piperidine derivatives used as orexin antagonists
1052012014973106/14/12 New medical use
1062012012868905/24/12 Anti-il-23 immunoglobulins
1072012012977805/24/12 Ligand that bind tgf-beta receptor rii
1082012011464705/10/12 Anti-serum album single variable domains
1092012010013704/26/12 Immunoglobulins
1102012010108304/26/12 S1p1 agonists comprising a bicyclic n-containing ring
1112012010108604/26/12 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1122012010112404/26/12 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1132012010113404/26/12 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1142012010113604/26/12 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1152012006517703/15/12 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1162012005896303/08/12 Macrolides with anti-inflammatory activity
1172012004625802/23/12 Novel crystalline pharmaceutical product
1182012004646902/23/12 Process for the preparation of a biphenyl-2-yl carbamic acid ester
1192012003982002/16/12 Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1202012004099102/16/12 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
1212012004102702/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1222012004102802/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1232012003431202/09/12 4-isopropyl-3-methylphenol for the treatment of inflammation
1242012000632201/12/12 Drug dispenser
1252012000422901/05/12 Substituted diketopiperazines and their use as oxytocin antagonists
1262011031937112/29/11 Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1272011030569212/15/11 Antigen-binding contructs
1282011030569312/15/11 Anitigen-binding constructs
1292011028809811/24/11 Novel compounds
1302011028190911/17/11 Substituted quinoline derivatives as h1 receptor antagonists
1312011027565511/10/11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1322011027566111/10/11 Tricyclic nitrogen compounds used as antibacterials
1332011026973811/03/11 Compounds
1342011026997011/03/11 Phenethanolamine derivatives for treatment of respiratory diseases
1352011026358810/27/11 Tricyclic compounds as glutamate receptor modulators
1362011025375210/20/11 Nozzle for a nasal inhaler
1372011025607410/20/11 Novel use
1382011024547010/06/11 Immunoglobulins
1392011023779209/29/11 Quinoline derivatives and their use as 5-ht6 ligands
1402011019027408/04/11 Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1412011017806307/21/11 Benzpyrazol derivatives as inhibitors of pi3 kinases
1422011016615007/07/11 Anhydrous crystal form of ovrepitant maleate
1432011015087106/23/11 Treatment of an autoimmune disease using il-18 antagonists
1442011015226206/23/11 Novel compounds
1452011014282406/16/11 Antibodies against amyloid-beta peptide
1462011014415106/16/11 Novel process, salts, composition and use
1472011013569506/09/11 Oral dosage form for controlled drug release
1482011013042306/02/11 Compounds which have activity at m1 receptor and their uses in medicine
1492011011719005/19/11 Pharmaceutical formulations
1502011011826105/19/11 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1512011006164603/17/11 Drug dispenser
1522011006474003/17/11 Antigen binding proteins
1532011006572503/17/11 Triazole amide derivatives for use in therapy
1542011005916703/10/11 Encapsulation of biologically active agents
1552011005997903/10/11 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1562011004502702/24/11 Adjuvant
1572011004613702/24/11 Pyrazole derivatives as p2x7 modulators
1582011003452402/10/11 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1592011002157801/27/11 Compounds which potentiate the ampa receptor and uses thereof in medicine
1602011000939401/13/11 Tricyclic nitrogen compounds and their use as antibacterial agents
1612011000963101/13/11 Phenethanolamine derivatives for treatment of respiratory diseases
1622010032999612/30/10 Novel combination of therapeutic agents
1632010032402212/23/10 Novel compounds
1642010031657912/16/10 Novel use of alkyl phosphate esters
1652010031766612/16/10 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1662010031767212/16/10 Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1672010030808212/09/10 Dispensing device
1682010031170612/09/10 Method of treatment of allergic rhinitis
1692010031173412/09/10 Spiro compounds useful as antagonists of the h1 receptor
1702010030382112/02/10 Immunoglobulins
1712010030510712/02/10 Quinoline derivatives and their use as 5-ht6 ligands
1722010030512712/02/10 Novel compounds
1732010030516612/02/10 Novel compounds
1742010029222411/18/10 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1752010029229511/18/10 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1762010028615211/11/10 N-phenyl hydrazides as modulators of the ghrelin receptor
1772010027590911/04/10 Actuator for an inhaler
1782010027385310/28/10 Novel isoindol derivatives as ep4 receptor agonists
1792010026769110/21/10 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1802010026773410/21/10 N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1812010025619910/07/10 Crystalline form of an antimalarial compound
1822010025691910/07/10 Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1832010023966609/23/10 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1842010022418509/09/10 Actuator for an inhaler
1852010022234909/02/10 Quinoline derivatives used to treat inflammatory and allergic diseases
1862010021679908/26/10 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1872010021683708/26/10 Glycine transport inhibitors
1882010021067208/19/10 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1892010020325608/12/10 Method and the application of powder material to substrates
1902010020424208/12/10 Piperazine derivative having affinity for the histamine h3 receptor
1912010020427308/12/10 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1922010019767908/05/10 Compounds
1932010019769908/05/10 I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1942010019076407/29/10 Novel compounds
1952010018477007/22/10 Compounds
1962010018499607/22/10 Process of amide formation
1972010017569807/15/10 Capsule
1982010017406507/08/10 Compounds
1992010014809106/17/10 Method and system for rapid phase luminescense spectroscopy analysis
2002010015219506/17/10 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
2012010014401606/10/10 Apparatus for the disruption of animal cells
2022010014475506/10/10 Novel compounds
2032010014482906/10/10 Novel receptor antagonists and their methods of use
2042010014504006/10/10 Benzazepine derivatives for the treatment of neurological disorders
2052010013727606/03/10 Compounds which potentiate ampa receptor and uses thereof in medicine
2062010013735306/03/10 Tricyclic compounds as antibacterials
2072010013737806/03/10 Pyridine compounds for the treatment of prostaglandin mediated diseases
2082010013742806/03/10 Oxygen containing heterocycles as glycine transporter inhibiting compounds
2092010013058305/27/10 Prolinamide derivatives as modulators of voltage-gated sodium channels
2102010011352105/06/10 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2112010011352805/06/10 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2122010011379605/06/10 Indole derivatives as s1p1 receptor
2132010010565204/29/10 Purines as cysteine protease inhibitors
2142010010568804/29/10 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2152010010575404/29/10 5-(4phenyl)prolinamide for treatment of epilepsy
2162010008742404/08/10 Tricyclic nitrogen containing heterocycles as antibacterial agents
2172010008750204/08/10 Indazoles used to treat estrogen receptor beta mediated disorders
2182010008766704/08/10 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2192010008183004/01/10 Methods of synthesizing n-hydroxysuccinimidyl carbonates
2202010007595303/25/10 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2212010007598203/25/10 Pyridinone derivative for the treatment of premature ejaculation
2222010006816603/18/10 Oral composition comprising dimethicone copolyol
2232010006940903/18/10 "novel compounds"
2242010006941603/18/10 Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2252010005905203/11/10 Sheet driver for use in a drug dispenser
2262010006309703/11/10 Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2272010005650203/04/10 Compounds
2282010005652703/04/10 Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2292010005659503/04/10 Pyrazole derivatives as p2x7 modulators
2302010004863902/25/10 Oxadiazole derivates as s1p1 receptor agonists
2312010004167202/18/10 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2322010002969902/04/10 Matrix metalloproteinase inhibitors
2332010001628701/21/10 Compounds having affinity for dopamine d3 receptor and uses thereof"
2342010001637101/21/10 Indole compounds
2352010001002101/14/10 Novel compounds
2362010000052801/07/10 Manifold for use in medicament dispenser
2372010000052901/07/10 Manifold for use in medicament dispenser
2382010000342001/07/10 Medicament dispenser
2392010000423001/07/10 Azatricyclic compounds and their use
2402010000424001/07/10 Indole compounds
2412009032595212/31/09 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2422009032603212/31/09 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2432009031849412/24/09 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2442009031852312/24/09 Benzoisoindole derivatives and their use as ep4 receptor agonists
2452009031853012/24/09 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2462009031238812/17/09 Benzo [f] isoindoles as ep4 receptor agonists
2472009031254612/17/09 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2482009030605212/10/09 Indenyl derivatives and use thereof for the treatment of neurological disorders
2492009029874212/03/09 Process for manufacturing lactose



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE